<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505868</url>
  </required_header>
  <id_info>
    <org_study_id>2011-0727</org_study_id>
    <secondary_id>NCI-2012-00059</secondary_id>
    <secondary_id>2011-0727</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT01505868</nct_id>
  </id_info>
  <brief_title>Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>An Open Label Phase I/II Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This partially randomized phase I/II trial studies cabazitaxel with or without carboplatin in&#xD;
      treating patients with previously treated prostate cancer that has spread to other areas of&#xD;
      the body and does not respond to treatment with hormones. Drugs used in chemotherapy, such as&#xD;
      cabazitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either&#xD;
      by killing the cells, by stopping them from dividing, or by stopping them from spreading. It&#xD;
      is not yet known whether giving cabazitaxel alone or with carboplatin is more effective in&#xD;
      treating prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dosage (MTD) of cabazitaxel-carboplatin in the phase I&#xD;
      portion of the study.&#xD;
&#xD;
      II. To evaluate progression free survival achieved with cabazitaxel-carboplatin versus&#xD;
      cabazitaxel alone in men with metastatic castration resistant prostate cancer (mCRPC) in the&#xD;
      phase II portion of the study.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess prostate-specific antigen (PSA) response rate (percentage of patients with &gt; 50&#xD;
      % decline).&#xD;
&#xD;
      II. To correlate changes in bone specific alkaline phosphatase and urine n-telopeptides with&#xD;
      response.&#xD;
&#xD;
      III. To evaluate overall survival. IV. To evaluate safety and toxicity. V. To evaluate&#xD;
      influence of the anaplastic phenotype on response to therapy. VI. To collect and archive&#xD;
      serum, plasma, and urine samples in study patients for later hypothesis generating&#xD;
      associations.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study followed by a randomized phase II study.&#xD;
&#xD;
      PHASE I: Patients receive cabazitaxel intravenously (IV) over 60-90 minutes and carboplatin&#xD;
      IV over 60-90 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PHASE II: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive cabazitaxel IV over 60-90 minutes on day 1. Treatment repeats every&#xD;
      21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients receive cabazitaxel IV over 60-90 minutes and carboplatin IV over 60-90&#xD;
      minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2012</start_date>
  <completion_date type="Actual">December 9, 2019</completion_date>
  <primary_completion_date type="Actual">December 9, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dosage (MTD) of Cabazitaxel-carboplatin in the Phase I Portion of Study</measure>
    <time_frame>6 months</time_frame>
    <description>The MTD was defined as the highest dose cohort studied in which one of six or fewer patients experienced a dose-limiting toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) of Cabazitaxel-carboplatin Versus Cabazitaxel in the Phase II Portion of Study</measure>
    <time_frame>From the first dose until progression of disease or death, whichever comes first, up to 5 years</time_frame>
    <description>PFS is the time from the first dose until progression of disease or death, whichever comes first. PFS times will be estimated using the Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen (PSA) Response Rate</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of participants with a greater than 50% decrease in measurable values of PSA during treatment from their baseline PSA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone-Specific Alkaline Phosphatase Response</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of participants with a greater than 50% decrease in measurable values of bone-specific alkaline phosphatase during treatment from their baseline values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine N-Telopeptides Response</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of participants with a greater than 50% decrease in measurable values of urine n-telopeptides during treatment from their baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Time from date of treatment start until date of death due to any cause or last follow up, up to 5 years</time_frame>
    <description>Time from date of treatment start until date of death due to any cause or last follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Most Common Grade 3-5 Adverse Events</measure>
    <time_frame>Time from date of treatment start until date of death due to any cause or last follow up, up to 5 years</time_frame>
    <description>Grade 3: Serious reaction which requires medical treatment Grade 4: Life threatening. Grade 5 Death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Castration Levels of Testosterone</condition>
  <condition>Castration-Resistant Prostate Carcinoma</condition>
  <condition>Lymphadenopathy</condition>
  <condition>Metastatic Prostate Carcinoma</condition>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Prostate Carcinoma Metastatic in the Bone</condition>
  <condition>Prostate Small Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (cabazitaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cabazitaxel IV over 60-90 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (cabazitaxel and carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cabazitaxel IV over 60-90 minutes and carboplatin IV over 60-90 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (cabazitaxel)</arm_group_label>
    <arm_group_label>Arm II (cabazitaxel and carboplatin)</arm_group_label>
    <other_name>Jevtana</other_name>
    <other_name>RPR-116258A</other_name>
    <other_name>Taxoid XRP6258</other_name>
    <other_name>XRP-6258</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (cabazitaxel and carboplatin)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (cabazitaxel)</arm_group_label>
    <arm_group_label>Arm II (cabazitaxel and carboplatin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic evidence of prostate adenocarcinoma&#xD;
&#xD;
          -  In addition to patients with adenocarcinoma, patients with &quot;anaplastic&quot; features are&#xD;
             also eligible as defined by at least one of the following: a) histologic evidence of&#xD;
             small cell prostate cancer (patients with small cell carcinoma on histology are not&#xD;
             required to demonstrate castration-resistant progression); b) any of the following&#xD;
             metastatic presentations: (i) exclusive visceral metastases; (ii) radiographically&#xD;
             predominant lytic bone metastases identified by plain X-ray or computed tomography&#xD;
             (CT) scan; (iii) bulky (&gt;= 5 cm in longest dimension) lymphadenopathy (iv) bulky (&gt;= 5&#xD;
             cm) tumor mass in the prostate/pelvis (v) low PSA (=&lt; 10 ng/ml) at initial&#xD;
             presentation (prior to androgen ablation or at symptomatic progression in the&#xD;
             castrate-setting) plus high volume (&gt;= 20) bone metastases; (vi) elevated serum&#xD;
             lactate dehydrogenase (LDH) (&gt;= 2 x ULN) or elevated serum carcinoembryonic antigen&#xD;
             (CEA) (&gt;= 2 x upper limit of normal [ULN]) in the absence of other etiologies; (vii)&#xD;
             short interval (=&lt; 180 days) to castrate-resistant progression following initiation of&#xD;
             hormonal therapy&#xD;
&#xD;
          -  Castration-resistant prostate cancer; patients must have surgical or ongoing chemical&#xD;
             castration (with luteinizing-hormone-releasing hormone [LHRH] agonists or LHRH&#xD;
             antagonists), with a baseline testosterone level &lt; 50 ng/dL&#xD;
&#xD;
          -  Metastatic disease; patients must have evidence for metastatic prostate cancer by bone&#xD;
             scan and/or CT/magnetic resonance imaging (MRI) (i.e., soft tissue, visceral, lymph&#xD;
             node); if lymph node, visceral and/or soft-tissue metastases are the only evidence of&#xD;
             metastasis, at least one lesion must be &gt;= 1.5 cm in diameter&#xD;
&#xD;
          -  Patients may have received prior treatment with androgen ablative therapies (such as&#xD;
             bicalutamide, ketoconazole, diethylstilbestrol [DES], abiraterone, Xtandi, ARN-509)&#xD;
             and/or &quot;targeted&quot; therapies (such as tyrosine kinase inhibitors); androgen ablative&#xD;
             therapies must be discontinued &gt;= 3 days prior to initiation of study treatment with&#xD;
             the exception of abiraterone and/or enzalutamide, which may be continued during study&#xD;
             treatment per the practice preference of the treating physician; patients who are&#xD;
             predicted to benefit from an antiandrogen withdrawal response should be tested for&#xD;
             this possibility before being considered for eligibility to this study; targeted&#xD;
             therapies must be discontinued &gt;= 2 weeks before initiation of study treatment&#xD;
&#xD;
          -  Both chemotherapy-naive and patients previously treated with chemotherapy are&#xD;
             eligible; chemotherapy pretreated patients may have received a maximum of two prior&#xD;
             systemic cytotoxic chemotherapies completed at least 3 weeks prior to initiation of&#xD;
             study treatment&#xD;
&#xD;
          -  Patients must have documented evidence of progressive disease as defined by any of the&#xD;
             following: a) PSA progression: minimum of 2 rising values (3 measurements) obtained a&#xD;
             minimum of 7 days apart with the last result being at least &gt;= 2.0 ng/mL; b) new or&#xD;
             increasing non-bone disease (by Response Evaluation Criteria In Solid Tumors&#xD;
             [RECIST]); c) positive bone scan with 2 or more new lesions (Prostate Cancer Working&#xD;
             Group [PCWG2])&#xD;
&#xD;
          -  For purposes of stratification, patients will be categorized as &quot;responders&quot; or&#xD;
             &quot;non-responders&quot; based on their response to prior docetaxel-based therapy; a)&#xD;
             responders will have demonstrated objective responses to first-line docetaxel as&#xD;
             determined by any of the following: 1. decrease in PSA level &gt;= 50% from baseline,&#xD;
             maintained for &gt;= 6 weeks; 2. partial or complete response in lymph nodes and soft&#xD;
             tissue metastases by RECIST; responders must have received &gt;= 225 mg/m^2 (~ 3 cycles)&#xD;
             of docetaxel; b) patients not meeting response criteria above will be considered as&#xD;
             non-responders; we anticipate 2 general categories of non-responders based on the&#xD;
             following disease phenotypes: 1. progressive disease on therapy without any objective&#xD;
             evidence of response (&quot;primary-resistant disease&quot;); progressive disease on therapy&#xD;
             with prior objective evidence of response, but response duration is =&lt; 6 weeks&#xD;
             (&quot;docetaxel refractory disease&quot;); non-responders are eligible even if they have&#xD;
             received &lt; 225 mg/m^2 of docetaxel&#xD;
&#xD;
          -  If present, peripheral neuropathy must be =&lt; grade 2&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500/ml (unless due to bone marrow infiltration by&#xD;
             tumor in which case ANC &gt;= 500/ml are allowed) (within 14 days before registration)&#xD;
&#xD;
          -  Platelets &gt;= 100,000/ml (unless due to bone marrow infiltration by tumor in which case&#xD;
             &gt;= 50,000/ml are allowed) (within 14 days before registration)&#xD;
&#xD;
          -  Total bilirubin =&lt; upper limit of normal with the exception of isolated&#xD;
             hyperbilirubinemia due to Gilbert's syndrome or if the patient has liver metastases&#xD;
             and/or acute tumor-associated illness =&lt; 4 x ULN (within 14 days before registration)&#xD;
&#xD;
          -  Serum glutamic-pyruvic transaminase (SGPT), (alanine aminotransferase [ALT]) AND/OR&#xD;
             serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =&lt;&#xD;
             1.5 x the ULN or if patient has liver metastases and/or acute tumor-associated&#xD;
             illness, =&lt; 4 x ULN (within 14 days before registration)&#xD;
&#xD;
          -  Patient has creatinine clearance &gt;= 30 ml/min using the Cockcroft-Gault equation&#xD;
             (within 14 days before registration)&#xD;
&#xD;
          -  Men whose partner is a woman of childbearing potential must be willing to consent to&#xD;
             using effective contraception while on treatment and for at least 3 months thereafter&#xD;
&#xD;
          -  Patient or his legally authorized representative must provide written informed consent&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radiation therapy (including palliative radiotherapy to a metastatic lesion) within 14&#xD;
             days or major surgery (e.g., open abdominal, pelvic, thoracic, orthopedic or&#xD;
             neurosurgery) within 28 days of the date of the first dose&#xD;
&#xD;
          -  Samarium-153 within 28 days of registration, or strontium-89 within 12 weeks (84 days)&#xD;
             of registration; patients who have received 2 or more doses of bone-seeking&#xD;
             radioisotopes are not eligible&#xD;
&#xD;
          -  Current treatment on another therapeutic clinical trial&#xD;
&#xD;
          -  Prior treatment with cabazitaxel and/or carboplatin&#xD;
&#xD;
          -  Impending complication from bone metastases (fracture and/or cord compression);&#xD;
             properly treated or stabilized fractures and/or cord compression is allowed&#xD;
&#xD;
          -  Presence of ongoing urinary obstruction (e.g., urinary retention, hydronephrosis)&#xD;
             requiring medical intervention; properly treated urinary obstruction is allowed&#xD;
&#xD;
          -  Patient has an uncontrolled intercurrent illness (e.g., uncontrolled diabetes,&#xD;
             uncontrolled hypertension)&#xD;
&#xD;
          -  Patient has another serious medical or psychiatric illness that could, in the&#xD;
             investigator's opinion, potentially interfere with the patient's ability to provide&#xD;
             informed consent or with the completion of treatment according to this protocol&#xD;
&#xD;
          -  Patients with a history of severe hypersensitivity reaction to JEVTANA® (cabazitaxel)&#xD;
             or other drugs formulated with polysorbate 80&#xD;
&#xD;
          -  Patients with an active second malignancy that could, in the investigator's opinion,&#xD;
             potentially interfere with the patient's ability to participate and/or complete this&#xD;
             trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Corn</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 30, 2011</study_first_submitted>
  <study_first_submitted_qc>January 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2012</study_first_posted>
  <results_first_submitted>April 1, 2021</results_first_submitted>
  <results_first_submitted_qc>July 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2021</results_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Lymphadenopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 12, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT01505868/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were treated at MD Anderson Cancer Center in Houston, TX and Karmanos Cancer institute in Detroit, MI</recruitment_details>
      <pre_assignment_details>170 participants enrolled, 10 were phase I participants, 1 participant withdrew in phase I</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I Cabazitaxel + Carboplatin Dose Zero</title>
          <description>Intravenous cabazitaxel 20 mg/m2 and carboplatin area under the curve (AUC) 3 mg/mL per min every 21 days</description>
        </group>
        <group group_id="P2">
          <title>Phase I Cabazitaxel + Carboplatin Dose One</title>
          <description>Intravenous cabazitaxel 20 mg/m2 and carboplatin area under the curve (AUC) 4 mg/mL per min every 21 days</description>
        </group>
        <group group_id="P3">
          <title>Phase I Cabazitaxel + Carboplatin Dose Two</title>
          <description>Intravenous cabazitaxel 25 mg/m2 and carboplatin area under the curve (AUC) 4 mg/mL per min every 21 days</description>
        </group>
        <group group_id="P4">
          <title>Phase II Cabazitaxel</title>
          <description>Intravenous cabazitaxel 25 mg/m2 every 21 days up to 10 doses</description>
        </group>
        <group group_id="P5">
          <title>Phase II Cabazitaxel + Carboplatin</title>
          <description>Intravenous cabazitaxel 25 mg/m2 and carboplatin AUC 4 every 21 days up to 10 doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="79"/>
                <participants group_id="P5" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="79"/>
                <participants group_id="P5" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I Cabazitaxel + Carboplatin Dose Zero</title>
          <description>Intravenous cabazitaxel 20 mg/m2 and carboplatin AUC 3 every 21 days up to 10 doses</description>
        </group>
        <group group_id="B2">
          <title>Phase I Cabazitaxel + Carboplatin Dose One</title>
          <description>Intravenous cabazitaxel 20 mg/m2 and carboplatin AUC 4 every 21 days up to 10 doses</description>
        </group>
        <group group_id="B3">
          <title>Phase I Cabazitaxel + Carboplatin Dose Two</title>
          <description>Intravenous cabazitaxel 25 mg/m2 and carboplatin AUC 4 every 21 days up to 10 doses</description>
        </group>
        <group group_id="B4">
          <title>Phase II Cabazitaxel</title>
          <description>Intravenous cabazitaxel 25 mg/m2 every 21 days up to 10 doses</description>
        </group>
        <group group_id="B5">
          <title>Phase II Cabazitaxel + Carboplatin</title>
          <description>Intravenous cabazitaxel 25 mg/m2 and carboplatin AUC 4 every 21 days up to 10 doses</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="79"/>
            <count group_id="B5" value="81"/>
            <count group_id="B6" value="169"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="55" upper_limit="77"/>
                    <measurement group_id="B2" value="74" lower_limit="72" upper_limit="78"/>
                    <measurement group_id="B3" value="69" lower_limit="66" upper_limit="72"/>
                    <measurement group_id="B4" value="66" lower_limit="61" upper_limit="69"/>
                    <measurement group_id="B5" value="68" lower_limit="62" upper_limit="73"/>
                    <measurement group_id="B6" value="67" lower_limit="61" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="81"/>
                    <measurement group_id="B6" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="55"/>
                    <measurement group_id="B6" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="81"/>
                    <measurement group_id="B6" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) performance status</title>
          <description>Grade 0: Fully active, able to carry on all pre-disease performance without restriction. Grade 1: Restricted in physically strenuous activity but ambulatory, able to carry out light house work, office work. Grade 2: Ambulatory and capable of all selfcare but unable to carry out any work activities awake at least 50% of day.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 and 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="59"/>
                    <measurement group_id="B6" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate-specific antigen (PSA)</title>
          <units>µg/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="380.4" lower_limit="21.1" upper_limit="653.3"/>
                    <measurement group_id="B2" value="89.5" lower_limit="27" upper_limit="160"/>
                    <measurement group_id="B3" value="217.6" lower_limit="6.7" upper_limit="551.8"/>
                    <measurement group_id="B4" value="23.7" lower_limit="8.6" upper_limit="81.2"/>
                    <measurement group_id="B5" value="33.8" lower_limit="11.4" upper_limit="146.3"/>
                    <measurement group_id="B6" value="28.75" lower_limit="8.6" upper_limit="146.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone metastases</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="75"/>
                    <measurement group_id="B6" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dosage (MTD) of Cabazitaxel-carboplatin in the Phase I Portion of Study</title>
        <description>The MTD was defined as the highest dose cohort studied in which one of six or fewer patients experienced a dose-limiting toxicity.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I Cabazitaxel + Carboplatin</title>
            <description>Intravenous cabazitaxel 25 mg/m2 and carboplatin area under the curve (AUC) 4 mg/mL per min every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dosage (MTD) of Cabazitaxel-carboplatin in the Phase I Portion of Study</title>
          <description>The MTD was defined as the highest dose cohort studied in which one of six or fewer patients experienced a dose-limiting toxicity.</description>
          <units>mg/m^2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS) of Cabazitaxel-carboplatin Versus Cabazitaxel in the Phase II Portion of Study</title>
        <description>PFS is the time from the first dose until progression of disease or death, whichever comes first. PFS times will be estimated using the Kaplan-Meier method.</description>
        <time_frame>From the first dose until progression of disease or death, whichever comes first, up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase II Cabazitaxel</title>
            <description>Intravenous cabazitaxel 25 mg/m2 every 21 days up to 10 doses</description>
          </group>
          <group group_id="O2">
            <title>Phase II Cabazitaxel + Carboplatin</title>
            <description>Intravenous cabazitaxel 25 mg/m2 and carboplatin AUC 4 every 21 days up to 10 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) of Cabazitaxel-carboplatin Versus Cabazitaxel in the Phase II Portion of Study</title>
          <description>PFS is the time from the first dose until progression of disease or death, whichever comes first. PFS times will be estimated using the Kaplan-Meier method.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="3.5" upper_limit="5.7"/>
                    <measurement group_id="O2" value="7.3" lower_limit="5.5" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate Specific Antigen (PSA) Response Rate</title>
        <description>Percentage of participants with a greater than 50% decrease in measurable values of PSA during treatment from their baseline PSA.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase II Cabazitaxel</title>
            <description>Intravenous cabazitaxel 25 mg/m2 every 21 days up to 10 doses</description>
          </group>
          <group group_id="O2">
            <title>Phase II Cabazitaxel + Carboplatin</title>
            <description>Intravenous cabazitaxel 25 mg/m2 and carboplatin AUC 4 every 21 days up to 10 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Specific Antigen (PSA) Response Rate</title>
          <description>Percentage of participants with a greater than 50% decrease in measurable values of PSA during treatment from their baseline PSA.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="30.2" upper_limit="51.8"/>
                    <measurement group_id="O2" value="61.7" lower_limit="51.4" upper_limit="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone-Specific Alkaline Phosphatase Response</title>
        <description>Percentage of participants with a greater than 50% decrease in measurable values of bone-specific alkaline phosphatase during treatment from their baseline values</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase II Cabazitaxel</title>
            <description>Intravenous cabazitaxel 25 mg/m2 every 21 days up to 10 doses</description>
          </group>
          <group group_id="O2">
            <title>Phase II Cabazitaxel + Carboplatin</title>
            <description>Intravenous cabazitaxel 25 mg/m2 and carboplatin AUC 4 every 21 days up to 10 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Bone-Specific Alkaline Phosphatase Response</title>
          <description>Percentage of participants with a greater than 50% decrease in measurable values of bone-specific alkaline phosphatase during treatment from their baseline values</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" lower_limit="19" upper_limit="39"/>
                    <measurement group_id="O2" value="62" lower_limit="51.4" upper_limit="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine N-Telopeptides Response</title>
        <description>Percentage of participants with a greater than 50% decrease in measurable values of urine n-telopeptides during treatment from their baseline values.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase II Cabazitaxel</title>
            <description>Intravenous cabazitaxel 25 mg/m2 every 21 days up to 10 doses</description>
          </group>
          <group group_id="O2">
            <title>Phase II Cabazitaxel + Carboplatin</title>
            <description>Intravenous cabazitaxel 25 mg/m2 and carboplatin AUC 4 every 21 days up to 10 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Urine N-Telopeptides Response</title>
          <description>Percentage of participants with a greater than 50% decrease in measurable values of urine n-telopeptides during treatment from their baseline values.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="33.2" upper_limit="76.8"/>
                    <measurement group_id="O2" value="62.5" lower_limit="42.1" upper_limit="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Time from date of treatment start until date of death due to any cause or last follow up.</description>
        <time_frame>Time from date of treatment start until date of death due to any cause or last follow up, up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase II Cabazitaxel</title>
            <description>Intravenous cabazitaxel 25 mg/m2 every 21 days up to 10 doses</description>
          </group>
          <group group_id="O2">
            <title>Phase II Cabazitaxel + Carboplatin</title>
            <description>Intravenous cabazitaxel 25 mg/m2 and carboplatin AUC 4 every 21 days up to 10 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Time from date of treatment start until date of death due to any cause or last follow up.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="13.8" upper_limit="21.9"/>
                    <measurement group_id="O2" value="18.5" lower_limit="16.7" upper_limit="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II Most Common Grade 3-5 Adverse Events</title>
        <description>Grade 3: Serious reaction which requires medical treatment Grade 4: Life threatening. Grade 5 Death.</description>
        <time_frame>Time from date of treatment start until date of death due to any cause or last follow up, up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase II Cabazitaxel</title>
            <description>Intravenous cabazitaxel 25 mg/m2 every 21 days up to 10 doses</description>
          </group>
          <group group_id="O2">
            <title>Phase II Cabazitaxel + Carboplatin</title>
            <description>Intravenous cabazitaxel 25 mg/m2 and carboplatin AUC 4 every 21 days up to 10 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II Most Common Grade 3-5 Adverse Events</title>
          <description>Grade 3: Serious reaction which requires medical treatment Grade 4: Life threatening. Grade 5 Death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatique</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Aggressive Variant Prostate Carcinoma-Metastatic (ACPC-MS) Phenotypes Correlated to Response</title>
        <description>PFS and OS were reported for participants with and without AVPC-MS in the cabazitaxel vs cabazitaxel + carboplatin treatment groups</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AVPC-MS Postive</title>
            <description>Immunochemistry positive for AVPC-MS</description>
          </group>
          <group group_id="O2">
            <title>AVPC-MS Negative</title>
            <description>Immunochemistry negative for AVPC-MS</description>
          </group>
        </group_list>
        <measure>
          <title>Aggressive Variant Prostate Carcinoma-Metastatic (ACPC-MS) Phenotypes Correlated to Response</title>
          <description>PFS and OS were reported for participants with and without AVPC-MS in the cabazitaxel vs cabazitaxel + carboplatin treatment groups</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cabazitaxel PFS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.3" upper_limit="NA">below the level of detection</measurement>
                    <measurement group_id="O2" value="6.3" lower_limit="5.9" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cabazitaxel + carboplatin PFS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="4.4" upper_limit="9.6"/>
                    <measurement group_id="O2" value="6.5" lower_limit="3.9" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cabazitaxel OS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="4.8" upper_limit="NA">below the level of detection</measurement>
                    <measurement group_id="O2" value="21.7" lower_limit="17.4" upper_limit="NA">below the level of detection</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cabazitaxel + carboplatin OS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="13.3" upper_limit="37.2"/>
                    <measurement group_id="O2" value="21.5" lower_limit="9.1" upper_limit="NA">below the level of detection</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase I Cabazitaxel + Carboplatin Dose Zero</title>
          <description>Intravenous cabazitaxel 20mg/m2 and carboplatin area under the curve (AUC) 3mg/mL per min every 21 days</description>
        </group>
        <group group_id="E2">
          <title>Phase I Cabazitaxel + Carboplatin Dose One</title>
          <description>Intravenous cabazitaxel 20 mg/m2 and carboplatin area under the curve (AUC) 4 mg/mL per min every 21 days</description>
        </group>
        <group group_id="E3">
          <title>Phase I Cabazitaxel + Carboplatin Dose Two</title>
          <description>Intravenous cabazitaxel 25 mg/m2 and carboplatin area under the curve (AUC) 4 mg/mL per min every 21 days</description>
        </group>
        <group group_id="E4">
          <title>Phase II Cabazitaxel</title>
          <description>Intravenous cabazitaxel 25 mg/m2 every 21 days up to 10 doses</description>
        </group>
        <group group_id="E5">
          <title>Phase II Cabazitaxel + Carboplatin</title>
          <description>Intravenous cabazitaxel 25 mg/m2 and carboplatin AUC 4 every 21 days up to 10 doses</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="69" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WBC decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="78" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="81" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="31" subjects_affected="20" subjects_at_risk="79"/>
                <counts group_id="E5" events="112" subjects_affected="47" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="23" subjects_affected="14" subjects_at_risk="79"/>
                <counts group_id="E5" events="58" subjects_affected="35" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="102" subjects_affected="44" subjects_at_risk="79"/>
                <counts group_id="E5" events="160" subjects_affected="54" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="11" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E5" events="14" subjects_affected="7" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="60" subjects_affected="28" subjects_at_risk="79"/>
                <counts group_id="E5" events="170" subjects_affected="57" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="14" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="25" subjects_affected="14" subjects_at_risk="79"/>
                <counts group_id="E5" events="63" subjects_affected="30" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E5" events="13" subjects_affected="10" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="125" subjects_affected="58" subjects_at_risk="79"/>
                <counts group_id="E5" events="272" subjects_affected="69" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E5" events="14" subjects_affected="9" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Localized Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Non-cardiac cest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E5" events="14" subjects_affected="12" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E5" events="11" subjects_affected="8" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="17" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E5" events="19" subjects_affected="8" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E5" events="32" subjects_affected="16" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E5" events="83" subjects_affected="32" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" events="14" subjects_affected="12" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>WBC decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="11" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E5" events="50" subjects_affected="24" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E5" events="21" subjects_affected="17" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" events="12" subjects_affected="8" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="17" subjects_affected="14" subjects_at_risk="79"/>
                <counts group_id="E5" events="24" subjects_affected="16" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" events="11" subjects_affected="6" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E5" events="18" subjects_affected="10" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E5" events="31" subjects_affected="13" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypomagnesenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E5" events="51" subjects_affected="35" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyponatrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="10" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Genralized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E5" events="16" subjects_affected="13" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E5" events="22" subjects_affected="16" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="10" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E5" events="18" subjects_affected="15" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E5" events="23" subjects_affected="16" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" events="14" subjects_affected="10" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urinary urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="34" subjects_affected="19" subjects_at_risk="79"/>
                <counts group_id="E5" events="71" subjects_affected="34" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Epitaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="79"/>
                <counts group_id="E5" events="26" subjects_affected="24" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" events="11" subjects_affected="8" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul Corn, MD PHD- Chair Ad Interim, Genitourinary Medical Oncology</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 563-7208</phone>
      <email>pcorn@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

